Loading...
Docoh
Log in Free sign up

AIM ImmunoTech (AIM)

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Company profile

Ticker
AIM
Exchange
NYSE
Website
aimimmuno.com
CEO
Thomas Equels
Employees
Incorporated
Florida
Location
Florida
Fiscal year end
Dec 31
Sector
Manufacturing > Biological Product (except Diagnostic) Manufacturing
Industry (SIC)
Biological Products, (No Diagnostic Substances)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne ...
Former names
HEMISPHERX BIOPHARMA INC
SEC CIK
0000946644
Corporate docs
Subsidiaries
BioPro Corp. • BioAegean Corp. • Hemispherx Biopharma Europe ...
IRS number
520845822

AIM stock data

News

From Benzinga Pro
Why IZEA Worldwide Shares Are Trading Higher By Over 30%: Here Are 37 Stocks Moving Premarket
16 Aug 22
Gainers IZEA Worldwide, Inc. (NASDAQ: IZEA) shares rose 30.8% to $1.19 in pre-market trading after the company reported a second-quarter revenue increase of 96% year-over-year to $12.58 million, beating the consensus of $9.75 million.
Recap: AIM ImmunoTech Q2 Earnings
15 Aug 22
AIM ImmunoTech (AMEX:AIM) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
AIM ImmunoTech Q2 EPS $(0.10) Up From $(0.12) YoY
15 Aug 22
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.10) per share. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year.
Earnings Scheduled For August 12, 2022
12 Aug 22
Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket
1 Aug 22

Press releases

From Benzinga Pro
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
15 Aug 22
AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases,
AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
15 Aug 22
– On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 – Well-positioned to achieve multiple near-term clinical and
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID
28 Jul 22
OCALA, Fla., July 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data
20 Jul 22
AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series
14 Jul 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

15 Aug 22
16 Aug 22
31 Dec 22

Financial summary

Financial statements Chart AIM financial data
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 34.45M 34.45M 34.45M 34.45M 34.45M 34.45M
Cash burn (monthly) (no burn) 557.5K 1.57M 1.6M 771K 1.19M
Cash used (since last report) n/a 875.91K 2.46M 2.52M 1.21M 1.87M
Cash remaining n/a 33.58M 31.99M 31.94M 33.24M 32.58M
Runway (months of cash) n/a 60.2 20.4 19.9 43.1 27.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

AIM insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
18 Jul 22 Equels Thomas K. Common Stock Grant Acquire A No No 0.76 32,895 25K 382,704
25 Apr 22 Equels Thomas K. Common Stock Grant Acquire A No No 1.02 49,020 50K 349,809
25 Apr 22 Iii Peter W. Rodino Common Stock Grant Acquire A No No 1.02 4,902 5K 63,193
25 Apr 22 Stewart Appelrouth Common Stock Grant Acquire A No No 1.07 24,500 26.22K 136,417
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

AIM institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Baxter International • Pfizer • Canada • Astrazeneca • Novartis • GSK • Axcella Health

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: Absent, acquire, activist, analyzing, attempt, attention, Bioscience, blind, campaign, Chancellor, Chancery, Chioini, composition, concert, connection, contest, context, costly, Court, declaratory, defective, Delaware, Deutsch, difficult, disregarded, District, divert, diverted, effectuate, enjoin, exploited, Franz, hearing, injunctive, instability, invalid, Jonathan, Jorgl, judgement, Kellner, Lautz, lawsuit, litigation, Merck, Michael, Middle, Monday, motion, Nederland, NJBC, nominate, nomination, noncompliance, notice, Octrooicentrum, ORR, Overview, perception, personnel, prevail, purported, purporting, pursuit, qualified, regular, relief, restraining, retain, Rice, satisfy, set, smallpox, speculative, stipulation, stockholder, sued, takeover, Ted, temporary, thereunder, Todd, TRO, Tudor, unanimously, unlawful, Vaccinia, Vice, Walter
Removed: administer, alleviate, bond, Casper, conservative, Contemporaneously, corporate, document, driven, embedded, employ, epithelial, exceed, expiring, exposure, FluMist, invest, investment, mutually, parallel, personal, recruiting, relocated, studied, temperature
From filing 10-Q 2022 Q2
Financial reports
View all
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
10-K
2021 FY
Annual report
31 Mar 22
10-Q
2021 Q3
Quarterly report
14 Nov 21
10-Q/A
2021 Q2
Quarterly report (amended)
17 Aug 21
10-Q
2021 Q2
Quarterly report
16 Aug 21
10-Q
2021 Q1
Quarterly report
17 May 21
10-K
2020 FY
Annual report
30 Mar 21
10-Q
2020 Q3
Quarterly report
12 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
Current reports
View all
8-K
AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid
18 Jul 22
8-K
AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing
21 Jun 22
8-K
Entry into a Material Definitive Agreement
17 Jun 22
8-K
Clinical Development Program for the Treatment of Pancreatic Cancer
12 Apr 22
8-K
Regulation FD Disclosure
28 Mar 22
8-K
Other Events
16 Mar 22
8-K
AIM ImmunoTech Announces Strategic Sale of New Brunswick, New Jersey
7 Mar 22
8-K
AIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer
3 Mar 22
8-K
Regulation FD Disclosure
27 Jan 22
8-K
Regulation FD Disclosure
26 Jan 22
Registration and prospectus
View all
S-8
Registration of securities for employees
1 Jul 22
S-3
Shelf registration
21 Jan 22
POS AM
Prospectus update (post-effective amendment)
18 Jan 22
S-8
Registration of securities for employees
1 Jul 21
424B5
Prospectus supplement for primary offering
18 Aug 20
S-8
Registration of securities for employees
3 Aug 20
424B5
Prospectus supplement for primary offering
15 Jun 20
424B5
Prospectus supplement for primary offering
10 Mar 20
424B5
Prospectus supplement for primary offering
3 Mar 20
424B4
Prospectus supplement with pricing info
26 Sep 19
Proxies
View all
DEFA14A
Additional proxy soliciting materials
15 Aug 22
DFAN14A
Additional proxy materials by non-management
21 Jul 22
DEF 14A
Definitive proxy
17 Aug 21
DEF 14A
Definitive proxy
11 Aug 20
DEF 14A
Definitive proxy
20 Aug 19
DEF 14A
Definitive proxy
23 Apr 19
PRE 14A
Preliminary proxy
5 Apr 19
DEF 14A
Definitive proxy
3 Aug 18
PRE 14A
Preliminary proxy
19 Jul 18
DEF 14A
Definitive proxy
17 Jul 17
Other
View all
EFFECT
Notice of effectiveness
7 Feb 22
CORRESP
Correspondence with SEC
30 Jan 22
UPLOAD
Letter from SEC
25 Jan 22
EFFECT
Notice of effectiveness
24 Jan 22
EFFECT
Notice of effectiveness
26 Sep 19
UPLOAD
Letter from SEC
25 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
UPLOAD
Letter from SEC
23 Sep 19
Ownership
View all
4
AIM ImmunoTech / Thomas K Equels ownership change
18 Jul 22
4
AIM ImmunoTech / STEWART APPELROUTH ownership change
27 Apr 22
4
AIM ImmunoTech / Peter W Rodino III ownership change
26 Apr 22
4
AIM ImmunoTech / Thomas K Equels ownership change
26 Apr 22
3
AIM ImmunoTech / Robert IV Dickey ownership change
4 Apr 22
4
AIM ImmunoTech / Peter W Rodino III ownership change
4 Mar 22
4
AIM ImmunoTech / WILLIAM M MITCHELL ownership change
4 Mar 22
4
AIM ImmunoTech / ELLEN M LINTAL ownership change
4 Mar 22
4
AIM ImmunoTech / Thomas K Equels ownership change
4 Mar 22
4
AIM ImmunoTech / STEWART APPELROUTH ownership change
4 Mar 22

Patents

Utility
Compositions and Methods for Cancer Therapy
31 Mar 22
One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound in any order together or separately.
Utility
Methods for Improving Exercise Tolerance In Myalgic Encephalomyelitis Patients
3 Mar 22
The present invention relates to methods for treating a subject with myalgic encephalomyelitis/chronic fatigue syndrome symptoms comprising administering a target subject a pharmaceutical composition comprising a therapeutic dsRNA (tdsRNA).
Utility
Compositions for Cancer Therapy and Methods
1 Jul 21
One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately.
Utility
Compositions for Cancer Therapy and Methods
24 Jun 20
One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately.

Reddit threads

View all